Sex differences in comorbidities and COVID-19 mortality-Report from the real-world data

Front Public Health. 2022 Aug 12:10:881660. doi: 10.3389/fpubh.2022.881660. eCollection 2022.

Abstract

Background: The differential effect of comorbidities on COVID-19 severe outcomes by sex has not been fully evaluated.

Objective: To examine the association of major comorbidities and COVID-19 mortality in men and women separately.

Methods: We performed a retrospective cohort analysis using a large electronic health record (EHR) database in the U.S. We included adult patients with a clinical diagnosis of COVID-19 who also had necessary information on demographics and comorbidities from January 1, 2016 to October 31, 2021. We defined comorbidities by the Charlson Comorbidity Index (CCI) using ICD-10 codes at or before the COVID-19 diagnosis. We conducted logistic regressions to compare the risk of death associated with comorbidities stratifying by sex.

Results: A total of 121,342 patients were included in the final analysis. We found significant sex differences in the association between comorbidities and COVID-19 death. Specifically, moderate/severe liver disease, dementia, metastatic solid tumor, and heart failure and the increased number of comorbidities appeared to confer a greater magnitude of mortality risk in women compared to men.

Conclusions: Our study suggests sex differences in the effect of comorbidities on COVID-19 mortality and highlights the importance of implementing sex-specific preventive or treatment approaches in patients with COVID-19.

Keywords: COVID-19 Research Database; COVID-19 mortality; comorbidities; real-world data; sex differences.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • COVID-19 Testing
  • COVID-19*
  • Comorbidity
  • Female
  • Humans
  • Male
  • Retrospective Studies
  • SARS-CoV-2
  • Sex Characteristics